Free Trial

Nuveen LLC Makes New $561,000 Investment in Aura Biosciences, Inc. $AURA

Aura Biosciences logo with Medical background

Key Points

  • Nuveen LLC has acquired a new stake in Aura Biosciences, purchasing 95,706 shares valued at approximately $561,000, representing about 0.19% ownership in the company.
  • Research firms have issued positive ratings for Aura Biosciences, with JMP Securities and HC Wainwright providing price targets of $19.00 and $22.00, respectively, signaling a favorable outlook on the stock.
  • The company reported earnings of ($0.47) per share for the last quarter, exceeding analyst expectations, with forecasts suggesting a projected -1.66 earnings per share for the current year.
  • MarketBeat previews top five stocks to own in November.

Nuveen LLC bought a new stake in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) during the 1st quarter, according to its most recent filing with the SEC. The fund bought 95,706 shares of the company's stock, valued at approximately $561,000. Nuveen LLC owned approximately 0.19% of Aura Biosciences as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in AURA. Wells Fargo & Company MN boosted its position in shares of Aura Biosciences by 27.3% during the 4th quarter. Wells Fargo & Company MN now owns 27,623 shares of the company's stock valued at $227,000 after acquiring an additional 5,930 shares in the last quarter. Barclays PLC boosted its position in shares of Aura Biosciences by 19.2% during the 4th quarter. Barclays PLC now owns 72,725 shares of the company's stock valued at $598,000 after acquiring an additional 11,715 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Aura Biosciences by 25.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 365,824 shares of the company's stock valued at $3,007,000 after acquiring an additional 73,062 shares in the last quarter. Northern Trust Corp boosted its position in shares of Aura Biosciences by 6.3% during the 4th quarter. Northern Trust Corp now owns 387,269 shares of the company's stock valued at $3,183,000 after acquiring an additional 23,006 shares in the last quarter. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Aura Biosciences during the 4th quarter valued at about $50,000. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Aura Biosciences

In other Aura Biosciences news, SVP Amy Elazzouzi sold 7,722 shares of the business's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $6.70, for a total value of $51,737.40. Following the completion of the transaction, the senior vice president directly owned 86,558 shares of the company's stock, valued at approximately $579,938.60. The trade was a 8.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.30% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Zacks Research upgraded shares of Aura Biosciences from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 19th. HC Wainwright reissued a "buy" rating and set a $22.00 price target on shares of Aura Biosciences in a report on Wednesday, August 13th. Finally, JMP Securities reissued a "market outperform" rating and set a $19.00 price target on shares of Aura Biosciences in a report on Friday, May 23rd. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $22.00.

Check Out Our Latest Stock Report on Aura Biosciences

Aura Biosciences Trading Down 2.6%

AURA stock traded down $0.17 during trading on Tuesday, hitting $6.31. 23,774 shares of the stock traded hands, compared to its average volume of 212,291. Aura Biosciences, Inc. has a one year low of $4.34 and a one year high of $12.38. The stock has a market cap of $391.67 million, a price-to-earnings ratio of -3.21 and a beta of 0.45. The company has a 50 day simple moving average of $6.64 and a 200 day simple moving average of $6.36.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. As a group, analysts predict that Aura Biosciences, Inc. will post -1.66 earnings per share for the current fiscal year.

Aura Biosciences Profile

(Free Report)

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

Featured Articles

Institutional Ownership by Quarter for Aura Biosciences (NASDAQ:AURA)

Should You Invest $1,000 in Aura Biosciences Right Now?

Before you consider Aura Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.

While Aura Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.